Virtu Financial LLC increased its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 665.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 271,537 shares of the company’s stock after acquiring an additional 236,044 shares during the quarter. Virtu Financial LLC’s holdings in Teva Pharmaceutical Industries were worth $5,849,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in TEVA. Panagora Asset Management Inc. raised its position in Teva Pharmaceutical Industries by 47.0% in the 3rd quarter. Panagora Asset Management Inc. now owns 402,884 shares of the company’s stock valued at $8,678,000 after buying an additional 128,792 shares during the last quarter. Radin Capital Partners Inc. purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $9,676,000. Korea Investment CORP raised its position in Teva Pharmaceutical Industries by 9.5% in the 3rd quarter. Korea Investment CORP now owns 605,633 shares of the company’s stock valued at $13,045,000 after buying an additional 52,600 shares during the last quarter. CIBC World Markets Inc. raised its position in Teva Pharmaceutical Industries by 9.6% in the 3rd quarter. CIBC World Markets Inc. now owns 536,143 shares of the company’s stock valued at $11,549,000 after buying an additional 46,887 shares during the last quarter. Finally, FMR LLC raised its position in Teva Pharmaceutical Industries by 19.1% in the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock valued at $527,341,000 after buying an additional 3,921,785 shares during the last quarter. 63.44% of the stock is owned by institutional investors.
In other Teva Pharmaceutical Industries news, insider Deborah A. Griffin sold 2,376 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the transaction, the insider now owns 2,376 shares in the company, valued at approximately $56,334.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Richard Daniell sold 2,488 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The disclosure for this sale can be found here. Insiders have sold a total of 6,531 shares of company stock valued at $152,749 in the last quarter. 0.43% of the stock is owned by corporate insiders.
TEVA stock opened at $22.19 on Monday. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.75. The firm has a market cap of $22.31 billion, a PE ratio of 5.65, a PEG ratio of 6.62 and a beta of 0.77. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $13.56 and a fifty-two week high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.11. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.54 billion. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The firm’s quarterly revenue was down 19.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.00 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.82 EPS for the current year.
Several equities research analysts have recently issued reports on the company. Mizuho raised their target price on Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, September 17th. Wells Fargo & Co set a $23.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, September 17th. Jefferies Financial Group reaffirmed a “hold” rating and set a $21.00 target price on shares of Teva Pharmaceutical Industries in a research report on Friday, August 3rd. Bank of America raised their target price on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the company an “underperform” rating in a research report on Friday, November 2nd. Finally, Cantor Fitzgerald set a $25.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Friday, September 14th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $22.08.
WARNING: This report was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://transcriptdaily.com/2018/11/26/virtu-financial-llc-purchases-236044-shares-of-teva-pharmaceutical-industries-ltd-teva.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.